CorMedix Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 CorMedix Inc 公司

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

CorMedix Inc简介



公司代码CRMD

公司名称CorMedix Inc

上市日期Mar 25, 2010

CEOTodisco (Joseph)

员工数量64

证券类型Ordinary Share

年结日Mar 25

公司地址300 Connell Drive

城市BERKELEY HEIGHTS

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编07922

电话19085179500

网址https://cormedix.com/

公司代码CRMD

上市日期Mar 25, 2010

CEOTodisco (Joseph)

CorMedix Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

567.46K

+77156.00%

Mr. Steven W. Lefkowitz

Independent Director

133.10K

+45453.00%

Ms. Susan Blum

Chief Financial Officer

132.74K

+63053.00%

Ms. Janet M. Dillione

Independent Director

43.93K

+20453.00%

Mr. Gregory Scott (Greg) Duncan

Independent Director

43.79K

+30453.00%

Mr. Robert Stewart

Independent Director

41.45K

+30453.00%

Mr. Myron M. Kaplan, J.D.

Independent Chairman of the Board

--

Dr. Alan William Dunton, M.D.

Independent Director

--

Ms. Elizabeth (Liz) Massonhurlburt

Chief Operating Officer

--

Dr. Matthew T. (Matt) David, M.D.

Chief Business Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

567.46K

+77156.00%

Mr. Steven W. Lefkowitz

Independent Director

133.10K

+45453.00%

Ms. Susan Blum

Chief Financial Officer

132.74K

+63053.00%

Ms. Janet M. Dillione

Independent Director

43.93K

+20453.00%

Mr. Gregory Scott (Greg) Duncan

Independent Director

43.79K

+30453.00%

Mr. Robert Stewart

Independent Director

41.45K

+30453.00%

收入明细

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

104.28M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 1月29日周四

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.69%

Marshall Wace LLP

4.41%

其他

71.37%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.69%

Marshall Wace LLP

4.41%

其他

71.37%

股东类型

持股股东

占比

Investment Advisor

27.93%

Hedge Fund

16.86%

Investment Advisor/Hedge Fund

15.45%

Individual Investor

8.00%

Research Firm

2.04%

Pension Fund

1.11%

Bank and Trust

0.32%

Insurance Company

0.03%

Venture Capital

0.03%

其他

28.22%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

368

50.21M

63.73%

+4.38M

2025Q3

340

43.85M

56.33%

+8.67M

2025Q2

304

34.76M

43.08%

+9.67M

2025Q1

267

24.95M

43.35%

-4.41M

2024Q4

241

23.99M

39.87%

+4.76M

2024Q3

216

19.17M

36.31%

+1.94M

2024Q2

207

17.23M

38.40%

-272.84K

2024Q1

207

17.37M

41.54%

-5.46M

2023Q4

207

18.82M

39.64%

+838.41K

2023Q3

199

17.96M

39.30%

-1.31M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.04M

6.4%

+248.22K

+5.18%

Sep 30, 2025

Deep Track Capital LP

4.96M

6.29%

+4.46M

+891.10%

Nov 21, 2025

Abdalkader (Shaibatalhamd Aymen)

4.65M

6.22%

+4.65M

--

Aug 08, 2025

The Vanguard Group, Inc.

3.96M

5.03%

-347.89K

-8.07%

Sep 30, 2025

Marshall Wace LLP

3.47M

4.41%

+893.52K

+34.63%

Sep 30, 2025

Deerfield Management Company, L.P.

3.32M

4.22%

+3.32M

--

Sep 30, 2025

State Street Investment Management (US)

1.84M

2.33%

+233.97K

+14.61%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.81M

2.3%

+213.45K

+13.37%

Sep 30, 2025

Citadel Advisors LLC

1.72M

2.18%

+2.87K

+0.17%

Sep 30, 2025

Alyeska Investment Group, L.P.

1.26M

1.6%

+512.98K

+68.40%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

2.01%

Invesco Biotechnology & Genome ETF

1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.52%

VictoryShares Small Cap Free Cash Flow ETF

0.79%

First Trust Active Factor Small Cap ETF

0.3%

Janus Henderson Small Cap Growth Alpha ETF

0.25%

ALPS Barron's 400 ETF

0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.19%

Vanguard US Multifactor ETF

0.16%

iShares Micro-Cap ETF

0.15%

State Street SPDR S&P Pharmaceuticals ETF

占比2.01%

Invesco Biotechnology & Genome ETF

占比1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.52%

VictoryShares Small Cap Free Cash Flow ETF

占比0.79%

First Trust Active Factor Small Cap ETF

占比0.3%

Janus Henderson Small Cap Growth Alpha ETF

占比0.25%

ALPS Barron's 400 ETF

占比0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比0.19%

Vanguard US Multifactor ETF

占比0.16%

iShares Micro-Cap ETF

占比0.15%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据